Table 3.
JNJ-47965567 does not alter proportions of T cell subsets in SOD1G93A mice. Spleens and CNS draining and non-draining lymph nodes from end stage β-CD- and JNJ-47965567-treated SOD1G93A mice were labelled with fluorochrome-conjugated mAb and the percentages of T cell subsets, as well as relative expression of CD39 (MFI), assessed by flow cytometry. Results are mean ± SEM
| Cell typea | Spleen | Draining lymph node | Non-draining lymph node | |||
|---|---|---|---|---|---|---|
| Vehicle (n = 14) | JNJ-47965567 (n = 21) | Vehicle (n = 14) | JNJ-47965567 (n = 19) | Vehicle (n = 14) | JNJ-47965567 (n = 20) | |
| % CD4+ of CD3+ | 54.8 ± 0.7 | 54.2 ± 2.1 | 48.3 ± 1.0 | 50.3 ± 0.6 | 49.2 ± 1.4 | 50.2 ± 0.8 |
| % CD44+ | 18.9 ± 1.1 | 16.9 ± 0.8 | 15.8 ± 0.8 | 16.0 ± 0.8 | 14.4 ± 1.0 | 14.9 ± 0.8 |
| CD39 MFI | 17.7 ± 3.8 | 15.2 ± 2.0 | 8.9 ± 1.1 | 9.0 ± 0.9 | 10.3 ± 2.2 | 8.0 ± 0.8 |
| % Foxp3+ (Treg) | 13.1 ± 0.7 | 12.8 ± 0.5 | 17.2 ± 0.7 | 18.2 ± 1.0 | 14.4 ± 0.6 | 15.5 ± 0.7 |
| % CD44+ | 25.5 ± 1.7 | 23.3 ± 1.1 | 40.5 ± 1.7 | 38.5 ± 1.6 | 43.0 ± 2.2 | 42.6 ± 1.9 |
| CD39 MFI | 27.2 ± 6.6 | 20.6 ± 2.1 | 15.5 ± 2.1 | 14.2 ± 1.4 | 20.3 ± 4.4 | 15.9 ± 1.3 |
| % Foxp3− (Tconv) | 87.2 ± 0.7 | 87.3 ± 0.5 | 83.1 ± 0.8 | 82.0 ± 1.0 | 85.7 ± 0.6 | 84.6 ± 0.7 |
| % CD44+ | 18.3 ± 1.2 | 16.9 ± 0.9 | 11.1 ± 0.8 | 11.7 ± 0.7 | 9.3 ± 0.7 | 9.5 ± 0.6 |
| CD39 MFI | 15.8 ± 3.4 | 13.7 ± 2.0 | 5.9 ± 0.7 | 6.2 ± 0.7 | 5.9 ± 1.3 | 4.4 ± 0.5 |
| % CD8+ of CD3+ | 33.3 ± 1.7 | 35.4 ± 0.7 | 41.0 ± 2.7 | 42.3 ± 0.8 | 41.3 ± 2.1 | 40.6 ± 1.2 |
| % CD44+ | 15.2 ± 1.3 | 12.7 ± 0.8 | 15.6 ± 1.3 | 13.0 ± 0.6 | 15.7 ± 1.6 | 14.8 ± 0.5 |
| CD39 MFI | 6.4 ± 1.8 | 5.3 ± 1.3 | 3.4 ± 0.6 | 2.6 ± 0.2 | 5.4 ± 1.7 | 2.9 ± 0.3 |
aTreg regulatory T cells, Tconv conventional T cells